A federal jury has awarded $250,000 to a Florida couple who claimed Novartis Pharmaceuticals failed to adequately warn of the risk of osteonecrosis of the jaw from taking the bone strengthening drug Zometa.
J. Hunter Chiles III will received $200,000 in compensatory damages under a » Continue Reading.
Irreconcilable contradictions in expert testimony prevented a product liability plaintiff from establishing that Merck failed to provide adequate warnings with the osteoporosis drug Fosamax, the 2nd Circuit has ruled in affirming judgment.
Six years after the first Fosamax lawsuit was filed, litigation over the osteoporosis drug is about to start a new chapter.
The suits against Merck, the drug’s manufacturer, fall into two categories: plaintiffs alleging they suffer from osteonecrosis, or jaw damage, and those claiming they suffered a non-traumatic femur fracture as a result of taking the drug.
A New Jersey appeals court yesterday upheld a defense verdict for Novartis Pharmaceuticals in a product liability lawsuit brought by a woman who claimed she developed osteonecrosis of the jaw after taking Aredia and Zometa.
After mixed results in bellwether cases, and a recent string of defense verdicts, a special settlement master has been appointed to the Fosamax multidistrict litigation.
A product liability plaintiff could not introduce evidence that the defendant added a new warning label to the osteoporosis drug that allegedly injured her husband, a U.S. District Court in New York has ruled in granting a motion in limine.
The doctrine of class action tolling applied to preserve the product liability lawsuit of a woman who claimed she suffered osteonecrosis of the jaw as a result of taking the prescription drug Zometa, the Montana Supreme Court has ruled.
A federal jury in North Carolina has returned a verdict of nearly $13 million against pharmaceutical giant Novartis, saying the company failed to adequately warn patients and doctors about the risks of taking the bone-strengthening drugs Zometa and Aredia.